| Variable | Univariable analysis | Multivariable analysis | HR | 95% Cl | value | HR | 95% Cl | value |
| Age (years) | <70 | Ref | | 0.083 | | | 0.018 | ≥70 | 1.45 | 0.95, 2.2 | | 1.71 | 1.1, 2.68 | | Clinical T stage | T1-T2b | Ref | | <0.001 | | | <0.001 | T2c | 0.77 | 0.34, 1.74 | | 0.53 | 0.22, 1.27 | | T3a | 1.6 | 0.62, 4.12 | | 0.95 | 0.33, 2.72 | | T3b-T4 | 4.01 | 1.78, 9.05 | | 1.82 | 0.65, 5.06 | | Initial PSA (ng/mL) | ≤10 | Ref | | <0.001 | Ref | | 0.609 | 10–20 | 1.4 | 0.79, 2.48 | | 1.24 | 0.69, 2.26 | | >20 | 2.62 | 1.55, 4.46 | | 1.36 | 0.73, 2.55 | | Gleason grade group | 1 | Ref | | <0.001 | | | | 2 | 1.65 | 0.84, 3.25 | | | | | 3 | 2.91 | 1.53, 5.53 | | | | | 4 | 4.58 | 2, 10.48 | | | | | 5 | 8.33 | 4.25, 16.33 | | | | | BMI (mg/m 2 ) | <25 | Ref | | 0.313 | | | | ≥25 | 1.24 | 0.82, 1.89 | | | | | NCCN risk classification | Low | Ref | | <0.001 | | | | Intermediate | 0.81 | 0.24, 2.7 | | | | | High | 1.62 | 0.49, 5.37 | | | | | Very high | 5.64 | 1.73, 18.32 | | | | | Margin status | Negative | Ref | | <0.001 | Ref | | 0.046 | Positive | 2.76 | 1.78–3.85 | | 1.52 | 1.01–2.29 | | LVI status | Negative | Ref | | <0.001 | | | | Positive | 2.33 | 1.45, 3.73 | | | | | Pathologic Gleason score | 6 | Ref | | <0.001 | | | 0.021 | 7 | 1.64 | 0.92, 2.91 | | 1.39 | 0.74, 2.61 | | ≥8 | 5.17 | 2.81, 9.5 | | 2.71 | 1.28, 5.74 | | pT stage | 1-2c | Ref | | <0.001 | Ref | | <0.001 | 3a | 1.93 | 0.99, 3.78 | | 2.78 | 1.6–4.83 | | 3b-4 | 5.83 | 3.7, 9.18 | | 5.15 | 3.07–8.64 | | pN stage | 0 | Ref | | 0.006 | Ref | | 0.028 | 1 | 3.06 | 1.53, 6.12 | | 3.1 | 1.65–5.81 | | Technique | Intraperitoneal | Ref | | | | | | Transperitoneal | 1.12 | 0.7, 1.79 | 0.638 | | | |
|
|